ARDS Stock - Aridis Pharmaceuticals, Inc.
Unlock GoAI Insights for ARDS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1.00M | $1.02M | $2.76M |
| Gross Profit | N/A | N/A | $1.00M | $1.02M | $2.76M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-29,993,000 | $-43,711,000 | $-22,401,000 | $-29,087,000 | $-24,117,000 |
| Net Income | $-30,749,000 | $-42,281,000 | $-22,333,000 | $-29,681,000 | $-22,105,000 |
| Net Margin | N/A | N/A | -2233.3% | -2904.2% | -801.8% |
| EPS | $-1.64 | $-3.44 | $-2.44 | $-3.43 | $-7.02 |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Visit WebsiteEarnings History & Surprises
ARDSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 4, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q3 2024 | Sep 27, 2024 | — | — | — | — |
Q2 2024 | Jun 27, 2024 | — | — | — | — |
Q1 2024 | Jan 1, 2024 | $-0.10 | — | — | — |
Q4 2023 | Nov 6, 2023 | $-0.10 | $-0.02 | +80.0% | ✓ BEAT |
Q3 2023 | Sep 13, 2023 | — | $0.33 | — | — |
Q2 2023 | May 22, 2023 | — | $-0.27 | — | — |
Q1 2023 | Mar 29, 2023 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q4 2022 | Nov 21, 2022 | $-0.15 | $-0.42 | -176.5% | ✗ MISS |
Q3 2022 | Aug 16, 2022 | $-0.06 | $-0.45 | -650.0% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.51 | $-0.44 | +13.7% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.58 | $-0.92 | -58.6% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.54 | $-1.94 | -259.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.57 | $-0.55 | +3.5% | ✓ BEAT |
Q2 2021 | May 11, 2021 | $-0.60 | $-0.77 | -28.3% | ✗ MISS |
Q1 2021 | Mar 30, 2021 | $-0.54 | $-0.59 | -9.3% | ✗ MISS |
Q4 2020 | Nov 20, 2020 | $-0.55 | $-0.65 | -18.2% | ✗ MISS |
Latest News
Frequently Asked Questions about ARDS
What is ARDS's current stock price?
What is the analyst price target for ARDS?
What sector is Aridis Pharmaceuticals, Inc. in?
What is ARDS's market cap?
Does ARDS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARDS for comparison